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Abstract: 
Background: Distal-to-proximal technique has been recommended for anti-cancer 
therapy administration. There is no evidence to suggest that a 24-hour delay of 
treatment is necessary for patients with a previous uncomplicated venous puncture 
proximal to the administration site.   
Objectives: This study aims to identify if the practice of 24-hour delay between a 
venous puncture and subsequent cannulation for anti-cancer therapies at a distal site is 
necessary for preventing extravasation. 
Methods: A prospective cohort study was conducted with 72 outpatients receiving 
anti-cancer therapy via an administration site distal to at least one previous 
uncomplicated venous puncture on the same arm in a tertiary cancer centre in 
Australia. Participants were interviewed and assessed at baseline data before 
treatment and on day 7 for incidence of extravasation/phlebitis. 
Results: Of 72 participants with 99 occasions of treatment, there was one incident of 
infiltration (possible extravasation) at the venous puncture site proximal to the 
administration site and two incidents of phlebitis at the administration site.  
Conclusions: A 24 hour delay is unnecessary if an alternative vein can be accessed 
for anti-cancer therapy after a proximal venous puncture. 
Implications for practice: Extravasation can occur at a venous puncture site 
proximal to an administration site in the same vein. However, the nurse can 
administer anti-cancer therapy at a distal site if the nurse can confidently determine 
the vein of choice is not in any way connected to the previous puncture site through 
visual inspection and palpation.  
 
 
 
4 
 
Introduction: 
Extravasation is a toxic local reaction caused by a drug or solution leaking into 
surrounding tissues, usually at the infusion site1. This is a serious complication of 
cytotoxic/vesicant  therapy, often causing severe local pain and ulceration; which may 
progress to tissue destruction that requires corrective surgery2-4. Extravasation is 
relatively uncommon, occurring in around 0.01-6.5% of cytotoxic infusions3, 5. They 
may be under-reported due to the delayed nature of some reactions6. This low 
incidence rate makes testing of interventions preventing extravasation with 
randomised controlled trials challenging and unrealistic. Risk factors associated with 
extravasation include poor vein quality, obesity, co-morbid conditions such as 
diabetes and circulatory disorders; impaired sensory perception, use of rigid cannulae, 
and clinicians’ lack of knowledge/skills7. 
 
The distal-to-proximal technique is the recommended clinical practice for preventing 
extravasation. This practice evolved from guidelines suggesting that intravenous anti-
cancer therapies should not be administered in a limb where proximal venous 
punctures have occurred within the previous 24 hours8. Although the guidelines 
suggest that the preferred site for anti-cancer treatment administration is “proximal to 
venous puncture sites established within the preceding 24 hours”1, and that 
practitioners should “avoid a vein that has been used for venous access in the previous 
24 hours to prevent leakage”3, the evidence on which these recommendations have 
been made is unclear. Sauerland and colleagues asserted that non-adherence to the 
distal-to-proximal technique increases the risk for extravasation injury8. 
 
However, most patients attending cancer care ambulatory units require phlebotomy 
for various tests before the administration of anti-cancer therapies. The cubital fossa is 
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the preferred site for phlebotomy, often occuring within several hours of a patient’s 
anti-cancer treatment9. In most cases, this is not a problem; the anti-cancer infusion 
may be administered through the alternate arm. However, a proportion of patients do 
not have this option, due to lymphatic surgery, peripheral neuropathy (grade 4) or 
poor venous access or other reasons. Therefore, treatment may be delayed and the 
patient required to return on the following day. Apart from patient inconvenience, 
which may be significant, there are also some concerns that delaying anti-cancer 
therapy may compromise the efficacy of treatment, particularly in a curative intent 
setting10, 11. The inefficiencies within the treatment suite and additional stress 
experienced by patients and their families have led us to attempt to validate the 
guidelines. Our prospective cohort study is the first to investigate the incidence of 
extravasation associated with anti-cancer therapies at the infusion site distal to a 
previous puncture.  
 
Methods 
Study Design 
A prospective cohort design with consecutive sampling was used in this study. 
Potential participants were recruited from a cancer care ambulatory unit of a tertiary 
cancer centre in Australia. Before the study began, the usual practice in our institution 
was that, no infusions were to be given at a site distal to a previous venous puncture 
within 24 hours. Over the study period, patients were administered anti-cancer 
therapies at a site distal to a previous venous puncture (phlebotomy or venous 
cannulation) if a proximal site could not be used. To our knowledge, there is no 
national guideline or policy that particularly informs practice in this area in Australia.  
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Patients receiving anti-cancer therapy with a proximal venous puncture (whether due 
to phlebotomy or cannulation attempts) to the anti-cancer infusion site within the 
previous 24 hours were eligible for inclusion. Patients were excluded if they were 
expected to have venous access (in the same limb) for the administration of other 
drugs, fluids or blood products within seven days; had a patent central venous access 
device (CVAD); were without access to a phone; or did not speak English. The study 
was approved by the Human Research and Ethics Committee at the Royal Brisbane 
and Women’s Hospital, and patient consent was obtained before data collection. A set 
of questionnaires were administered on the day of anti-cancer therapy before drug 
administration and on day 7 post administration by a research nurse with an extensive 
experience in the administration of anti-cancer therapy. To facilitate the telephone 
interviews, patients were given a copy of the day 7 interview questionnaire including 
all the assessment scales and the Venous Puncture Assessment Tool (VPAT). Due to 
the cyclic nature of anti-cancer therapies, participants could be recruited on multiple 
occasions if they remained eligible for the subsequent presentations.  
 
Procedures 
The research nurse approached all eligible participants to explain the study. 
Participants were then consented. The consent could occur before or after cannulation 
for treatment as long as the participant fit the inclusion criteria of the study. At 
recruitment, the research nurse completed a baseline questionnaire. This included 
information about demographics and risk factors related to the development of 
complications, and the locations of venous punctures associated with anti-cancer 
therapy. On day 7 (+/- 24 hours), participants were advised to return to the clinic to be 
assessed by the research nurse. At the time of assessment, participants were asked 
about the condition of the infusion site and any other venous puncture sites above or 
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below the infusion site. Patients who could not return on day 7 were interviewed by 
phone. For those who returned to the clinic, both patient subjective assessment and 
nurse face-to-face assessment were carried out for inter-rater reliability. As part of 
routine clinical care, all patients were educated by their nurses to report any concerns 
immediately, or as soon as they identify any signs and symptoms associated with 
extravasation, even before day 7. The research nurse used an interview guide to 
ensure the consistency of speech across all interviews. All participants received an 
exact copy of the assessment tools to assist with the interview process via the phone.  
 
Intruments 
For the assessment of venous complications, the Vein Assessment Tool (VAT) 12, the 
Infusion Nurses Society Standards of Practice Infiltration Scale (INS- SPIS) 13, and 
the Infusion Nurses Society Standards of Practice Phlebitis Scale (INS-SPPS) 13, 14 
were used. The scoring for VAT ranges from 0-2, with  0 indicating good vein quality, 
1= fair vein quality, and 2= poor vein quality12. The scoring for the INS-SPIS ranges 
from 0-4, with 0 indicating no symptoms and 4 indicating the most severe symptoms 
associated with infiltration/ extravasation13. The scoring for the INS-SPPS ranges 
from 0-4, with 0 indicating no symptoms and 4 indicating the most severe symptoms 
of phlebitis. A diagnosis of extravasation required a review and confirmation by a 
medical officer. In this study, a new assessment tool, the Venous Puncture 
Assessment Tool (VPAT) including the anterior and posterior views of the both arms, 
was developed in collaboration with the Herston Multimedia Unit, Royal Brisbane 
and Women’s Hospital to identify all puncture and administration sites (see Fig 1). 
The aim of the VPAT was to assist participants and the nurse to easily identify where 
previous puncture sites were on follow-up.  
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INSERT FIGURE 1 
 
Data analysis 
Data were entered and analyzed using SPSS®, version 17.0. The sample is described 
using frequencies for categorical data (such as gender and type of cancer/ anti-cancer 
therapy) and means/standard deviations for continuous data (such as age and 
haemoglobin). Using the number of participants enrolled in the study as the 
denominator and the total number of these participants who develop either an 
extravasation or phlebitis as numerators, we planned to calculate the proportion of 
participants developing an injury following administration of a cytotoxic infusion and 
their 95% confidence intervals. Rating between the research nurse and participants for 
extravasation and phlebitis were analysed using intraclass correlation coefficient. 
 
Results 
Participant Characteristics 
In total, 3942 patients were screened for eligibility at the Oncology Day Therapy 
Unit. Eighty-two participants were eligible. Of these,  77 (94%)  agreed to participate 
and 72 (88%)  completed the study. A total of 99 cannulations occurred among the 72 
participants between November 2010 and February 2011. All were for anti-cancer 
therapy and administered at a site distal to a previous venous puncture (a phlebotomy 
or failed cannulation attempts) in the same arm. Of the 99 occasions of anti-cancer 
treatment, 17  (16.83%) included at least one vesicant in the treatment protocol.  In 66 
cannulations, participants had at least one venous puncture at a  proximal site due to 
phlebotomy. For phlebotomy, 21 gauge needles were used. For cannulation, 22 gauge 
and 24 gauge needles were used. The number of cannulation attempts required for 
anti-cancer therapy ranged from one to seven in the same arm. The total number of 
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venous puntures including phlebotomy ranged from two to eight in the same arm (see 
Table 4). 
 
The demographic characteristics, medical and treatment information for the 77 
participants are summarised in Table 1-3. The mean age was 58.4 (SD=17.7). The 
majority of participants were male (n=44, 62.1%). The mean vein access score was 
0.5 (SD=0.7), indicating good to fair vein quality. The intraclass correlation 
coefficient for the rating of extravasation and phlebitis between the research nurse 
assessment and the participants was 1. Five participants could not be contacted for 
day 7 interview and were lost to follow up.  
 
INSERT TABLE 1 
INSERT TABLE 2  
INSERT TABLE 3  
INSERT TABLE 4 
 
Incidence of complications 
Of the 99 occasions of treatment, one infiltration was reported in one participant 
immediately at completion of the anti-cancer therapy. The infiltration occured at the 
proximal venous puncture site, which was complicated by a failed cannulation 
attempt. A 22 gauge needle was used during the failed cannulation attempt. The 
participant who developed an infiltration was  a 30 year-old obese woman with no 
other known risk factors. The participant had a diagnosis of squamous cell carcinoma 
of the cervix, (stage IIB), receiving 80mg cisplatin at 40mg/m2/dose, over 60 minutes. 
This participant also received 1 litre of Normal Saline (0.9% Sodium Chloride) for 
both pre- and post-hydration over 1 hour each. This incident occurred after regular 
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working hours and the participant was not reviewed by a medical officer. 
Furthermore, it was unable to be determined whether the infiltration was caused by 
the chemotherapy or post-hydration fluid. The immediate assessment identified an 
infiltration score of 2: skin blanched, gross odema (2.5-15 cm), cool to touch, without 
pain. As a matter of precaution, extravasation management as per local policy was 
implemented. The patient was instructed to apply cold compresses for 15-20 minutes 
four times a day over the next 48 hours. The participant was also advised to return the 
next day to the clinic for follow up assessment, however the participant did not return. 
On day 7 follow-up, the participant presented with an an infiltration score of 1 with 
odema <2.5 cm persisting at the proximal venous puncture site. The vein where a 
previous puncture for cannulation occurred and the distal infusion site was determined 
to be the same vein through palpation and visual inspection. This participant was the 
only one who received treatment at a site distal to a previous venous puncture in the 
same vein. 
 
Phlebitis 
Of the 99 occasions of treatment , there were no incidence of phlebitis at the venous 
puncture sites proximal to the anti-cancer therapy administration site. One participant, 
who received 1640mg gemcitabine at 1000mg/m2/dose over 30 minutes, developed 
phlebitis on two occasions between day 0 to day 7. The phlebitis was located within 
the vein in which the anti-cancer therapy was administered, between the distal 
administration site and the previous proximal venous punctures on each occasion. 
There were no signs of phlebitis at the previous venous puncture sites (phlebotomy 
sites).  
 
Discussion 
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There is a lack of evidence underpinning the clinical practice of a 24-hour delay if the 
distal-to-proximal technique is not followed. Our study is the first to investigate the 
implications of administering anti-cancer therapies (including a range of vesicant and 
non-vesicant solutions) via a site distal to a previous venous puncture. All of the 
participants in this study received their anti-cancer therapy via an administration site 
distal to at least one previous venous puncture on the same arm, without any evidence 
of extravasation. In preparation for this study, a new instrument, the Venous Puncture 
Assessment Tool (VPAT) was developed (Fig 1); in collaboration with the 
multimedia unit at our institution. Using the VPAT, the participants and the nurse 
were able to identify all prior puncture sites during the telephone interview. It was 
easy to use by both the nurse and participants, and we believe it will be a useful 
addition to those involved in intravenous assessment practice and research.  
 
The participants in this study had reasonably good vein access as measured by the 
VAT instrument. However, an average of three cannulation attempts proximal to the 
site for therapy administration were required. The usual practice in our institution was 
that the administration nurse could have two cannulation attempts. After two attempts, 
the nurse was to refer to a more experienced clinician (a nurse or a doctor). There was 
no specific policy with regards to the criteria for CVAD insertion in patients with 
numerous failed attempts at our institution. Therefore, patients were referred for 
CVAD insertion at the discretion of their treating clinicians. The participants in this 
cohort were mild or moderately unwell, recording, on average at least one 
comorbidity, which is probably consistent with the general cancer population.  
 
Although an incident of extravasation could not be confirmed in this case, the finding 
of this study did support the claim that a leakage of fluid can occur within 24 hours at 
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a proximal venous puncture site if the same vein is used. In other words, the distal-to-
proximal technique should still be considered when an alternative vein in the same 
arm cannot be accessed for anti-cancer therapy.  
 
Limitations 
The sample size in this study is relatively small. However, this is the first prospective 
study investigating a very important clinical question of interest. The incidence rates 
of extravasation and phlebitis were low and consistent with the literature. This may be 
due to high venepuncture skill levels among the experienced cancer care nurses 
involved in the trial. However, anti-cancer therapies are generally administered in 
units where high skill levels are available, so there is no reason why our findings may 
not be generalised to those units where staff are well trained in venepuncture 
procedures. It is also noteworthy that there were no patients with low platelet counts 
in this cohort. Participants with thrombocytopenia may need to receive extra caution 
as they may have delayed clotting and healing at the venous puncture site, which 
could, potentially increase the risk of extravasation.  
 
Implications for Practice 
The distal-to-proximal cannulation technique is recommended for anti-cancer therapy 
administration. While there remains a lack of evidence suggesting that administration 
at a site distal to the previous venous puncture may increase the risk of extravasation, 
our study reported that infiltration can occur at a venous puncture site proximal to an 
administration site in the same vein. However, the nurse can administer anti-cancer 
therapy at distal site if the nurse can confidently determine the vein of choice is not in 
any way connected to the previous puncture site through visual inspection, palpation 
or the use of a radiologic appliance. The nurse must have a good knowledge of the 
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anatomy of the veins of the arm. Consequently, there may be a case for modifying the 
guidelines to suggest that a 24 hour delay between a venous puncture and subsequent 
cannulation may not be necessary if an alternative vein in the same arm is available 
for use. Unnecessary delay of treatment that can increase the distress level of patients, 
cause a delay to the treatment regimen, and reduce the efficiency of care in a high 
volume cancer care ambulatory setting, can be avoided by effective nursing 
management.  
 
Conclusion 
A 24 hour delay is not necessary if an alternative vein that is not in any way 
connected to the previous puncture site can be accessed for anti-cancer therapy. 
However, this study provides evidence that a leakage of intravenous fluid can occur at 
a previous puncture site proximal to the administration site if the same vein is used.  
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Table 1. Sample demographic characteristics 
 Mean SD Range 
Age 58.4 17.7 18-90 
Height (cm) 169.3 9.1 150-191 
Weight (kg) 82.5 24.2 42-179 
 Groups Frequency Percentage 
Gender M 
F 
44 
28 
61.1% 
38.9% 
Ethicity Caucasians 
African 
South Pacific 
Islanders 
 
67 
1 
4 
 
 
93% 
1.4% 
5.6% 
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Table 2. Medical characteristics 
 
 Groups Frequency Percantage 
Type of cancer Haematological 
Head and Neck 
Lung 
Gynaecological 
Breast 
Genitourinary 
Gastroenterology 
CNS 
Sacoma 
23 
11 
8 
8 
7 
7 
6 
1 
1 
31.9% 
15.3% 
11.1% 
11.1% 
9.7% 
9.7% 
8.3% 
1.4% 
1.4% 
Metastasis Yes 
No 
22 
50 
65.3% 
34.7% 
 Mean SD Range 
Haemaglobin (g/L) 125.3 17.0 80-182 
White cells count 
(x109) 
7.6 4.8 2.7-32.7 
Platelets (x109) 254.1 116.6 111-692 
Neutrophils (x109) 5.3 4.5 0.9-29.6 
Number of 
comorbidities 
1.0 1.2 0-4 
Number of prior 
venuous punctures 
3.1 1.2 2-8 
Vein Assessment 
Tool (VAT) 
0.5 0.7 0-2 
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Table 3. Drug classification and number of cycle 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Drug classification Count 
Alkylating agent 
Antimetabolite 
Antitumour antibiotic 
Bisphosphonate  
Mitotic inhibitor 
Miscellaneous 
Monoclonal antibody 
Platinum compound 
Taxanes 
Topoisomerase I Inhibitors 
15 
14 
14 
1 
12 
2 
17 
27 
14 
1 
 Mean SD Range 
Number of cycle 4.6 5.4 1-34 
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Table 4. Number of cannulation attempts required for anti-cancer therapy in the same 
arm and total number of venous punctures in the same arm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Number of cannulation attempts Count  
One  
Two 
Three  
Four  
Five  
Seven  
51 
20 
20 
6 
1 
1 
Total number of venous punctures (including 
cannulation attempts and phlebotomy) 
Count 
Two 
Three 
Four 
Five 
Six 
Eight 
62 
20 
11 
4 
1 
1 
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